Acceleration of biosimilar business, debt reduction to be key priorties in FY25: Biocon Chief

​Despite competition in key US market, Biocon has been able to grow market share of three products from FY23 to FY24 - Fulphila (pegfilgrastim), used to reduce the chance of infections for patients undergoing chemotherapy from 14 per cent to 21 per cent; anti-breast cancer drug Ogivri (trastuzumab) from 10 per cent to 18 per cent, anti-diabetes Semglee (insulin glargine) from 10 per cent to 19 per cent (including closed managed care).